Full Press Release Details
Update on Regulatory Review of Lecanemab for Early Alzheimer’s Disease by the European Commission.
BIIB
Update on Regulatory Review of Lecanemab for Early Alzheimer’s Disease by the European Commission
Key Takeaway: Update on Regulatory Review of Lecanemab for Early Alzheimer’s Disease by the European Commission
Price reaction · baseline $115.17 (2025-04-11 close) · 1 other BIIB headline(s) in the window, move may be shared
day 0 close · peak
+3.6%
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceBest trade, last catalyst
+34%
120-day peak, hindsight
Typical move
1.8%
average across 15 past catalysts
Lead asset
Alefacept
Phase 3 · Chronic Plaque Psoriasis